|
gptkbp:instanceOf
|
gptkb:antibiotic
monobactam
|
|
gptkbp:approvalYear
|
1986
|
|
gptkbp:ATCCode
|
J01DF01
|
|
gptkbp:brand
|
gptkb:Cayston
Azactam
|
|
gptkbp:CASNumber
|
78110-38-0
|
|
gptkbp:chemicalClass
|
gptkb:antibiotic
|
|
gptkbp:contraindication
|
hypersensitivity to aztreonam
|
|
gptkbp:discoveredBy
|
gptkb:Squibb
|
|
gptkbp:eliminationHalfLife
|
1.5 to 2 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C13H17N5O8S2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aztreonam
|
|
gptkbp:indication
|
septicemia
urinary tract infections
intra-abdominal infections
gynecological infections
cystic fibrosis (inhaled form)
lower respiratory tract infections
skin and skin structure infections
|
|
gptkbp:KEGGID
|
D00220
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:MedlinePlusID
|
a693003
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
435.44 g/mol
|
|
gptkbp:notEffectiveAgainst
|
Gram-positive bacteria
anaerobic bacteria
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
B (US)
B1
|
|
gptkbp:proteinBinding
|
56-60%
|
|
gptkbp:PubChem_CID
|
55289
CHEMBL558
DB00355
|
|
gptkbp:routeOfAdministration
|
intramuscular
inhalation
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
rash
local injection site reactions
|
|
gptkbp:spectrumOfActivity
|
Gram-negative bacteria
|
|
gptkbp:synonym
|
Aztreonam for injection
Aztreonam lysine
|
|
gptkbp:UNII
|
P57A5T989J
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:beta-lactam_antibiotics
gptkb:monobactams
|
|
gptkbp:bfsLayer
|
6
|